NCT03081715 is a NA clinical trial of PD-1 Knockout T Cells in Esophageal Cancer, sponsored by Hangzhou Cancer Hospital.

Who is sponsoring NCT03081715?

NCT03081715 is sponsored by Hangzhou Cancer Hospital.

What drugs are being tested in NCT03081715?

Interventions in NCT03081715: PD-1 Knockout T Cells.

What condition does NCT03081715 study?

NCT03081715 studies Esophageal Cancer.

Is NCT03081715 still recruiting?

NCT03081715 is currently completed. Last updated 12 June 2019.

Last reviewed 2019-06-12 · How we verify

NCT03081715

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

PD-1 Knockout Engineered T Cells for Advanced Esophageal Cancer

Completed NA Last updated 12 June 2019

What this trial tests

NA trial testing PD-1 Knockout T Cells in Esophageal Cancer in 16 participants. Completed in 28 February 2018.

Timeline

14 March 2017

Primary endpoint
23 January 2018

28 February 2018

Quick facts

Lead sponsor	Hangzhou Cancer Hospital
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	16
Start date	14 March 2017
Primary completion	23 January 2018
Estimated completion	28 February 2018
Sites	1 location across China

Drugs / interventions tested

PD-1 Knockout T Cells — full drug profile →

Conditions studied

Esophageal Cancer — all drugs for Esophageal Cancer →

Sponsor

Hangzhou Cancer Hospital

Who can join

Adults 18 to 80, any sex, with Esophageal Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study will evaluate the safety of PD-1 knockout engineered T cells in treating advanced esophageal cancer. Blood or tissue samples will also be collected for research purposes.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Repair of double-strand breaks induced by CRISPR-Cas9 leads to large deletions and complex rearrangements.
Kosicki M, Tomberg K, Bradley A. · · 2018 · cited 1325× · PMID 30010673 · DOI 10.1038/nbt.4192
Applications of genome editing technology in the targeted therapy of human diseases: mechanisms, advances and prospects.
Li H, Yang Y, Hong W, Huang M, et al · · 2020 · cited 733× · PMID 32296011 · DOI 10.1038/s41392-019-0089-y
Exploring treatment options in cancer: Tumor treatment strategies.
Liu B, Zhou H, Tan L, Siu KTH, et al · · 2024 · cited 536× · PMID 39013849 · DOI 10.1038/s41392-024-01856-7
Combination Immunotherapy with CAR T Cells and Checkpoint Blockade for the Treatment of Solid Tumors.
Grosser R, Cherkassky L, Chintala N, Adusumilli PS. · · 2019 · cited 457× · PMID 31715131 · DOI 10.1016/j.ccell.2019.09.006
CRISPR-Based Therapeutic Genome Editing: Strategies and In Vivo Delivery by AAV Vectors.
Wang D, Zhang F, Gao G. · · 2020 · cited 405× · PMID 32243786 · DOI 10.1016/j.cell.2020.03.023
CRISPR Gene Therapy: Applications, Limitations, and Implications for the Future.
Uddin F, Rudin CM, Sen T. · · 2020 · cited 329× · PMID 32850447 · DOI 10.3389/fonc.2020.01387
Current applications and future perspective of CRISPR/Cas9 gene editing in cancer.
Wang SW, Gao C, Zheng YM, Yi L, et al · · 2022 · cited 305× · PMID 35189910 · DOI 10.1186/s12943-022-01518-8
Strategies in the delivery of Cas9 ribonucleoprotein for CRISPR/Cas9 genome editing.
Zhang S, Shen J, Li D, Cheng Y. · · 2021 · cited 266× · PMID 33391496 · DOI 10.7150/thno.47007

Verify or expand the search:

Other trials of PD-1 Knockout T Cells

Trials testing the same drug.

NCT03525652 — Therapeutic Vaccine Plus PD-1 Knockout in Prostate Cancer Treatment · Phase 1, PHASE2 · unknown
NCT02793856 — PD-1 Knockout Engineered T Cells for Metastatic Non-small Cell Lung Cancer · Phase 1 · completed

Other recruiting trials for Esophageal Cancer

Currently open trials in the same condition.

NCT07464470 — Comparison of Molecular-Genetic Concordance of the Primary Tumor and Brain Metastases of Gastroesophageal Cancers · recruiting
NCT07431281 — Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Meta · Phase 3 · recruiting
NCT07448493 — Local Treatment Strategies for Brain Metastases of Gastric and Esophageal Cancer · active not recruiting
NCT07410676 — EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
NCT07307560 — High-Flow Nasal Cannula for Preventing Hypoxia During Sedated Endoscopy in High-Risk Obstructive Sleep Apnea Patients · NA · recruiting

Other Hangzhou Cancer Hospital trials

Trials by the same sponsor.

NCT04481100 — CCRT With Itraconazole in Locally Advanced Squamous Esophageal Cancer · Phase 2 · unknown
NCT03554889 — Immunotherapy of Advanced Cancer Using a Combination Nimotuzumab and NK Cells · Phase 1 · unknown
NCT03200691 — Neoadjuvant Anti-PD-1 Antibody SHR-1210 and Radiation in Resectable Esophageal Squamous Cell Carcinoma · Phase 2 · unknown
NCT03187314 — Combination of Radiation Therapy and Anti-PD-1 Antibody SHR-1210 in Treating Patients With Esophageal Cancer · Phase 2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03081715 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Hangzhou Cancer Hospital
Last refreshed: 12 June 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03081715.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing